Ratio raises $50M as radiopharma field finds its groove
17 Jan 2024
Acquisition
Radiopharmaceutical biotech Ratio Therapeutics has raised a $50 million Series B to bring its first therapeutic into the clinic, it said Wednesday morning.
The biotech has now
raised
a total of $90 million since its founding in mid-2021. Based in Boston’s Seaport District, the biotech
unveiled
itself in June 2022 and has already inked collaborations with Bayer,
Merck
and Lantheus.
Radiopharma companies have been in the news with considerably more frequency in recent months with
two
key
acquisitions
by Eli Lilly and Bristol Myers Squibb, and financing rounds rolling in for a string of startups, like
Artbio
,
Convergent Therapeutics
and
Abdera Therapeutics
. Bristol Myers invested in Ratio’s Series B. The expanding market is also
causing CDMOs
to iron out supply chain bumps and configure access to raw materials.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.